Unraveling the potential of senescence-related genes in guiding clinical therapy of lung adenocarcinoma patients
Tóm tắt
Lung adenocarcinoma (LUAD) is the most common histological type of lung cancer. In recent years, cell senescence emerges as a potential therapeutic target of cancer therapy. However, the role of cell senescence in LUAD has not been comprehensively unveiled. One single cell RNA sequencing (scRNA-seq) dataset (GSE149655) and two bulk RNA-seq datasets (TCGA and GSE31210) of LUAD were included. Seurat R package was used to process scRNA-seq data and identify immune cell subgroups. Single sample gene set enrichment analysis (ssGSEA) was performed to calculate enrichment score of senescence-related pathways. Senescence-based molecular subtyping for LUAD samples was conducted through unsupervised consensus clustering. pRRophetic package was introduced to analysis drug sensitivity. The senescence-associated risk model was established using univariate regression and stepAIC methods. Western blot, RT-qPCR, immunofluorescence assay and CCK-8 were used to explore the effect of CYCS in LUAD cell lines. Malignant immune cells had remarkedly higher enrichment of senescence-related pathways than non-malignant cells. P53 signaling and DNA damage telomere stress induced senescence pathways were found to be significantly activated in LUAD samples compared with normal samples. We identified two clusters (clust1 and clust2) based on senescence-related genes. Clust1 had severe genomic instability, aggravated senescent features, and low immune and stromal infiltration. The senescence-associated risk model including CASP9, CHEK1, CYCS, SERPINE1, SESN2, TP53I3, LMNB1, RAD50 and TERF2IP, was effective to distinguish high- and low-risk groups. Moreover, low-risk group exhibited sensitive responses to immunotherapy and chemotherapeutic drugs. In vitro experiments results showed that CYCS expression was increased and promoted cell viability in LUAD cell lines. This study explored the important role of senescence in LUAD progression, and confirmed the potential of senescence-related genes in predicting LUAD prognosis and response to immunotherapy and chemotherapy.
Tài liệu tham khảo
Alique M, Sánchez-López E, Bodega G, Giannarelli C, Carracedo J, Ramírez R (2020) Hypoxia-inducible factor-1α: the master regulator of endothelial cell senescence in vascular aging. Cells 9(1)
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (london, England) 389(10064):67–76
Battram AM, Bachiller M, Martín-Antonio B (2020) Senescence in the development and response to cancer with immunotherapy: a double-edged sword. Int J Mol Sci 21(12)
Behmoaras J, Gil J (2021) Similarities and interplay between senescent cells and macrophages. J Cell Biol 220(2)
Blanche P, Dartigues JF, Jacqmin-Gadda H (2013) Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 32(30):5381–5397
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639
Buechler MB, Fu W, Turley SJ (2021) Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer. Immunity 54(5):903–915
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS et al (2016) Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 48(6):607–616
Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol (clifton NJ) 1711:243–259
Chen KY, Chen CC, Chang YC, Chang MC (2019) Resveratrol induced premature senescence and inhibited epithelial-mesenchymal transition of cancer cells via induction of tumor suppressor Rad9. PLoS One 14(7):e0219317
Clough E, Barrett T (2016) The Gene Expression Omnibus Database. Methods Mol Biol (clifton NJ) 1418:93–110
(2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543-50
Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J et al (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6(12):2853–2868
Cortesi M, Zanoni M, Pirini F, Tumedei MM, Ravaioli S, Rapposelli IG, et al (2021) Pancreatic cancer and cellular senescence: tumor microenvironment under the spotlight. Int J Mol Sci 23(1)
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE et al (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12(3):245–255
Dang HH, Ta HDK, Nguyen TTT, Anuraga G, Wang CY, Lee KH et al (2022) Prospective role and immunotherapeutic targets of sideroflexin protein family in lung adenocarcinoma: evidence from bioinformatics validation. Funct Integr Genomics 22(5):1057–1072
De Jaeghere EA, Denys HG, De Wever O (2019) Fibroblasts fuel immune escape in the tumor microenvironment. Trends Cancer 5(11):704–723
Gao R, Bai S, Henderson YC, Lin Y, Schalck A, Yan Y et al (2021) Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol 39(5):599–608
Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C et al (2019) Cellular senescence: defining a path forward. Cell 179(4):813–827
Gribov A, Sill M, Lück S, Rücker F, Döhner K, Bullinger L et al (2010) SEURAT: visual analytics for the integrated analysis of microarray data. BMC Med Genomics 3:21
Hänzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550–1558
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45(D1):D353–D361
Kelly J, Ali Khan A, Yin J, Ferguson TA, Apte RS (2007) Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Investig 117(11):3421–3426
Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 98(21):12072–12077
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS (2010) The essence of senescence. Genes Dev 24(22):2463–2479
Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P (2015) The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 1(6):417–425
Liu JY, Souroullas GP, Diekman BO, Krishnamurthy J, Hall BM, Sorrentino JA et al (2019) Cells exhibiting strong p16(INK4a) promoter activation in vivo display features of senescence. Proc Natl Acad Sci USA 116(7):2603–2611
Liu H, Zhao H, Sun Y (2021) Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies. Semin Cancer Biol 86(Pt 3):769–781
Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E et al (2013) A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 24(2):229–241
Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2(4):R41
Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A (2020) Role of p53 in the regulation of cellular senescence. Biomolecules 10(3)
Muz B, de la Puente P, Azab F, Azab AK (2015) The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (auckland NZ) 3:83–92
Oishi Y, Manabe I (2016) Macrophages in age-related chronic inflammatory diseases. NPJ Aging Mech Dis 2:16018
Pérez-Mancera PA, Young AR, Narita M (2014) Inside and out: the activities of senescence in cancer. Nat Rev Cancer 14(8):547–558
Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G et al (2021) Therapy-induced senescence: opportunities to improve anticancer therapy. J Natl Cancer Inst 113(10):1285–1298
Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, Biton M et al (2013) A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24(2):242–256
Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC et al (2016) Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun 7:11762
Salas-Benito D, Eguren-Santamaria I, Sanmamed MF (2021) Senescent T cells as a resistance mechanism to lung cancer immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 27(2):374–376
Shay JW (2016) Role of telomeres and telomerase in aging and cancer. Cancer Discov 6(6):584–593
Shen W, Song Z, Xiao Z, Huang M, Shen D, Gao P et al (2022) Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. IMeta 1(3):e36
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550
Tirpe AA, Gulei D, Ciortea SM, Crivii C, Berindan-Neagoe I (2019) Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int J Mol Sci 20(24)
Tomczak K, Czerwińska P, Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (poznan Poland) 19(1a):A68-77
Wang L, Lankhorst L, Bernards R (2022) Exploiting senescence for the treatment of cancer. Nat Rev Cancer 22(6):340–355
Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics (oxford England) 26(12):1572–1573
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445(7128):656–660
Yasuda T, Baba H, Ishimoto T (2021) Cellular senescence in the tumor microenvironment and context-specific cancer treatment strategies. FEBS J
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612
Zhang Z (2016) Variable selection with stepwise and best subset approaches. Ann Transl Med 4(7):136
Zhang XP, Liu F, Wang W (2011) Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci USA 108(22):8990–8995
Zhang X, Lan Y, Xu J, Quan F, Zhao E, Deng C et al (2019) Cell Marker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res 47(D1):D721–D728
Zhang J, He T, Xue L, Guo H (2021) Senescent T cells: a potential biomarker and target for cancer therapy. EBioMedicine 68:103409
Zhou R, Zhou J, Muhuitijiang B, Tan W (2022) Construction and experimental validation of a B cell senescence-related gene signature to evaluate prognosis and immunotherapeutic sensitivity in bladder cancer. Funct Integr Genomics 23(1):3